PLASMA AND URINARY CONCENTRATIONS OF METHAMPHETAMINE AFTER ORAL-ADMINISTRATION OF FAMPROFAZONE TO MAN

被引:21
作者
OH, ES [1 ]
HONG, SK [1 ]
KANG, GI [1 ]
机构
[1] SOOKMYUNG WOMENS UNIV,COLL PHARM,YONGSAN KU,SEOUL 140742,SOUTH KOREA
关键词
D O I
10.3109/00498259209046649
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. To obtain further evidence for the metabolic formation of methamphetamine from famprofazone in man, concentrations of methamphetamine in plasma, as well as in urine, were measured by g.l.c. In addition, intact famprofazone and famprofazone N-oxide were analysed in the urine. 2. Methamphetamine appeared in plasma 1 h after a single 100 mg dose of the drug to two male subjects, and the concentration maintained between 24 and 44 ng/ml over 2-12 h, declining to 10 ng/ml and an undetectable level respectively after 24 h. 3. Total urinary excretion of methamphetamine over 72 h was 1.9 mg for a 25 mg dose and 2.2 mg for a 50 mg dose. After a 100 mg dose, 4.6 mg of methamphetamine was excreted over 36 h. Neither intact famprofazone nor famprofazone N-oxide were detected when the urine samples after the 100 mg dose were examined. 4. The results provide further evidence that methamphetamine is a bona fide human metabolite of famprofazone and suggest that at least 20% dose may be broken down via the pathways leading to the formation of methamphetamine. This could have significant clinical implications as the result of pharmacological activity of this metabolite.
引用
收藏
页码:377 / 384
页数:8
相关论文
共 9 条
[1]   URINARY EXCRETION KINETICS OF METHYLAMPHETAMINE IN MAN [J].
BECKETT, AH ;
ROWLAND, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1965, S 17 :S109-&
[2]  
BRATER DC, 1984, PHARMACOKINETIC BASI, P119
[3]   DETERMINATION OF THERAPEUTIC BLOOD LEVELS OF METHAMPHETAMINE AND PENTOBARBITAL BY GC [J].
DRISCOLL, RC ;
BARR, FS ;
GRAGG, BJ ;
MOORE, GW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (10) :1492-&
[4]  
ELELLA DA, 1984, ARCH PHARM, V317, P89
[5]  
MARTINDALE, 1989, EXTRAPHARMACOPOEIE, P16
[6]  
MRONGOVIUS R, 1984, EUR J MED CHEM, V19, P161
[7]  
Neugebauer M, 1984, J Pharm Biomed Anal, V2, P53, DOI 10.1016/0731-7085(84)80089-8
[8]  
SINNIGER PA, 1954, SCHWEIZERISCHE MED W, V84, P351
[9]  
YOSHIMURA H, 1971, CHEM PHARM BULL, V19, P41